Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:

‍

With recent advances in Alzheimer’s research, and an expected increase in future cases, bioethicist Emily Largent discusses the need for new Alzheimer’s clinical trials policies, and more caregiver support and resources. (Penn Today)

Rhiannon Williams of MIT Technology Review looks at the new apps Visible, and Lungy, designed to help fight long COVID-19, among other illnesses.

Developed with the help of UW School of Medicine’s Institute for Protein Design, a new vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) is undergoing phase 1 human clinical trials. (Daily UW)
‍

‍
‍

Our Culture

“I’ve been at the company over seven years, and it’s been really cool to watch the company grow and continue to increase how we help our clients. One of the many things I like about my job is that it’s not always the same thing every day, because each client is unique. It makes every day interesting.

Judi is a platform. It’s an adjudication tool, but it’s also more. It’s a whole collaborative workflow process tool. It works with DSMB, Eligibility, anything.”

   –Stephen, Lead Engineer

‍‍
‍

About Judi

Judi speeds and improves the world's clinical trial workflows. Our cloud-based platform has 120,000 users across 168 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.

‍

‍

‍

‍